NYSE:PKI - PerkinElmer Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $141.73
  • Forecasted Upside: -8.36 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.45 (0.95%)

This chart shows the closing price for PKI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PerkinElmer Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PKI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PKI

Analyst Price Target is $141.73
▼ -8.36% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for PerkinElmer in the last 3 months. The average price target is $141.73, with a high forecast of $193.00 and a low forecast of $45.00. The average price target represents a -8.36% upside from the last price of $154.65.

This chart shows the closing price for PKI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 contributing investment analysts is to buy stock in PerkinElmer. This rating has held steady since April 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/15/2021Wolfe ResearchUpgradeMarket Perform ➝ OutperformLow
2/3/2021CitigroupBoost Price Target$150.00 ➝ $155.00High
1/7/2021Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$140.00 ➝ $175.00N/A
12/11/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$140.00 ➝ $150.00Low
12/11/2020Smith Barney CitigroupBoost Price Target$140.00 ➝ $150.00Low
12/2/2020The Goldman Sachs GroupInitiated CoverageBuy$160.00Low
11/12/2020The Goldman Sachs GroupInitiated CoverageBuy$50.00Low
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$150.00Medium
11/9/2020Needham & Company LLCBoost Price TargetBuy$139.00 ➝ $193.00High
10/29/2020Smith Barney CitigroupBoost Price Target$120.00 ➝ $140.00Low
10/29/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$130.00 ➝ $140.00Low
10/29/2020Robert W. BairdBoost Price TargetOutperform$137.00 ➝ $151.00High
9/11/2020Needham & Company LLCUpgradeHold ➝ Buy$139.00High
8/10/2020BMO Capital MarketsBoost Price TargetOutperform$44.00 ➝ $45.00Low
7/29/2020JPMorgan Chase & Co.Boost Price TargetNeutral$85.00 ➝ $105.00High
7/29/2020Stifel NicolausBoost Price TargetBuy$95.00 ➝ $125.00High
7/29/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$105.00 ➝ $130.00High
7/29/2020CfraUpgradeHold ➝ BuyHigh
7/13/2020Needham & Company LLCInitiated CoverageHoldHigh
5/7/2020UBS GroupBoost Price TargetNeutral$95.00 ➝ $96.00Low
5/6/2020Robert W. BairdBoost Price TargetOutperform$94.00 ➝ $99.00Low
5/6/2020CfraLower Price TargetHold$100.00 ➝ $94.00Low
5/6/2020JPMorgan Chase & Co.Boost Price TargetNeutral$80.00 ➝ $85.00Medium
4/28/2020UBS GroupLower Price TargetNeutral$100.00 ➝ $95.00Low
4/20/2020CitigroupBoost Price TargetNeutral$70.00 ➝ $85.00Low
4/2/2020JPMorgan Chase & Co.Lower Price TargetOverweight$49.00 ➝ $45.00High
4/2/2020Stifel NicolausLower Price TargetBuy$102.00 ➝ $80.00Low
3/30/2020Wells Fargo & CompanyLower Price TargetEqual Weight$100.00 ➝ $80.00Low
3/26/2020BarclaysLower Price TargetEqual Weight$100.00 ➝ $94.00Medium
3/20/2020CitigroupLower Price TargetNeutral$100.00 ➝ $70.00Low
1/28/2020UBS GroupBoost Price TargetNeutral$92.00 ➝ $100.00High
1/14/2020TD SecuritiesBoost Price TargetBuy$54.00 ➝ $56.00Medium
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$105.00Low
1/6/2020CitigroupInitiated CoverageNeutral$100.00Medium
1/3/2020Needham & Company LLCInitiated CoverageHold$79.00Medium
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform$89.00 ➝ $114.00High
11/21/2019Stifel NicolausReiterated RatingBuyLow
11/14/2019Stifel NicolausInitiated CoverageBuy$102.00High
11/5/2019Raymond JamesReiterated RatingBuy ➝ Average$51.00Low
10/31/2019Needham & Company LLCReiterated RatingHoldHigh
10/31/2019Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$104.00 ➝ $89.00High
10/18/2019UBS GroupLower Price TargetNeutral$101.00 ➝ $92.00Low
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$105.00Low
7/30/2019UBS GroupBoost Price TargetNeutral$99.00 ➝ $101.00High
7/19/2019Wood & CompanyReiterated RatingAverage$49.00Medium
7/10/2019Raymond JamesInitiated CoverageOutperformLow
5/30/2019Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
5/3/2019Royal Bank of CanadaReiterated RatingHold$41.00Low
4/9/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$115.00High
2/2/2019UBS GroupSet Price TargetHold$92.00Low
2/1/2019Piper Jaffray CompaniesBoost Price TargetOverweight$104.00Medium
1/16/2019DesjardinsReiterated RatingBuy ➝ Average$45.00Low
1/10/2019CIBCReiterated RatingBuy ➝ Average$44.50Medium
1/6/2019CowenReiterated RatingHold$85.00Low
1/3/2019Morgan StanleyLower Price TargetOverweight ➝ Overweight$100.00 ➝ $86.00Low
1/2/2019Needham & Company LLCInitiated CoverageHold ➝ Hold$79.00High
11/2/2018Janney Montgomery ScottDowngradeBuy ➝ NeutralMedium
10/10/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$95.00 ➝ $100.00High
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$100.00Low
9/10/2018Deutsche Bank AktiengesellschaftBoost Price TargetHold ➝ Hold$88.00 ➝ $93.00Low
9/5/2018BarclaysUpgradeUnderweight ➝ Equal Weight$79.00 ➝ $90.00Low
8/30/2018Cleveland ResearchUpgradeNeutral ➝ BuyMedium
8/2/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$83.00 ➝ $86.00Low
8/2/2018CowenReiterated RatingHold$85.00Low
8/2/2018Robert W. BairdReiterated RatingBuy$89.00Low
8/2/2018BarclaysBoost Price TargetUnderweight ➝ Underweight$73.00 ➝ $79.00High
8/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $95.00High
5/1/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$85.00 ➝ $90.00High
5/1/2018Bank of AmericaLower Price TargetNeutral ➝ Hold$86.00 ➝ $83.00High
5/1/2018Robert W. BairdLower Price TargetOutperform ➝ Outperform$88.00 ➝ $82.00High
5/1/2018Janney Montgomery ScottLower Price TargetBuy ➝ Fair Value$92.00 ➝ $73.36High
4/11/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$89.00 ➝ $85.00Low
4/9/2018Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$85.00 ➝ $80.00Low
1/26/2018BarclaysBoost Price TargetUnderweight ➝ Underweight$69.00 ➝ $73.00Low
1/26/2018CowenReiterated RatingHold$84.00Low
1/26/2018Robert W. BairdReiterated RatingBuy$88.00Medium
1/3/2018Evercore ISIInitiated CoverageIn-Line$77.00Low
12/19/2017Bank of AmericaUpgradeUnderperform ➝ Neutral$78.00Low
11/3/2017Morgan StanleyBoost Price TargetOverweight$77.00 ➝ $78.00N/A
11/3/2017Robert W. BairdBoost Price TargetOutperform$75.00 ➝ $78.00N/A
10/20/2017Jefferies Financial GroupReiterated RatingHold$70.00N/A
10/20/2017Robert W. BairdReiterated RatingBuy$72.00N/A
10/6/2017Morgan StanleyReiterated RatingOverweight$79.00 ➝ $77.00N/A
9/26/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$67.00Low
9/26/2017CitigroupReiterated RatingBuy$74.00 ➝ $80.00Low
9/1/2017CowenReiterated RatingHold$70.00Low
8/7/2017CitigroupBoost Price TargetBuy$67.00 ➝ $74.00Medium
8/4/2017Piper Jaffray CompaniesReiterated RatingBuy$81.00Medium
7/25/2017Piper Jaffray CompaniesBoost Price TargetOverweight$80.00Medium
7/16/2017Cantor FitzgeraldReiterated RatingHoldLow
7/13/2017Wells Fargo & CompanyInitiated CoverageMarket Perform ➝ Market Perform$72.00Low
7/10/2017Morgan StanleyReiterated RatingOverweight$73.00 ➝ $79.00Low
6/22/2017Evercore ISIReiterated RatingIn-Line$62.50 ➝ $68.00Low
6/21/2017Cantor FitzgeraldReiterated RatingNeutralLow
6/20/2017Jefferies Financial GroupReiterated RatingHold$58.00 ➝ $69.00Medium
6/20/2017CowenReiterated RatingMarket Perform$61.00 ➝ $70.00Low
6/19/2017Cantor FitzgeraldSet Price TargetHold$65.00High
5/15/2017Jefferies Financial GroupReiterated RatingHold$49.00Low
5/15/2017Cantor FitzgeraldReiterated RatingHold$65.00Low
5/6/2017BarclaysSet Price TargetSell$55.00Low
5/5/2017Cantor FitzgeraldReiterated RatingHold$65.00High
5/5/2017Jefferies Financial GroupReiterated RatingHold$49.00High
4/19/2017Cantor FitzgeraldDowngradeOverweight ➝ Neutral$60.00Low
4/7/2017CitigroupBoost Price TargetBuy$57.00 ➝ $67.00Low
3/27/2017Janney Montgomery ScottUpgradeNeutral ➝ BuyMedium
2/5/2017BTIG ResearchReiterated RatingHoldN/A
2/3/2017Bank of AmericaDowngradeNeutral ➝ Underperform$48.00N/A
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$55.00N/A
12/25/2016Cantor FitzgeraldSet Price TargetBuy$60.00N/A
11/8/2016BarclaysReiterated RatingSell$50.00N/A
9/22/2016UBS GroupReiterated RatingBuy$56.00 ➝ $61.00N/A
8/5/2016JPMorgan Chase & Co.Boost Price TargetNeutral$52.00 ➝ $55.00N/A
8/5/2016Jefferies Financial GroupBoost Price TargetHold$52.00 ➝ $55.00N/A
8/5/2016Morgan StanleySet Price TargetBuy$61.00N/A
8/5/2016BarclaysBoost Price TargetUnderweight$50.00 ➝ $52.00N/A
8/5/2016BTIG ResearchReiterated RatingHoldN/A
8/5/2016MizuhoDowngradeBuy ➝ Neutral$56.00N/A
7/22/2016BTIG ResearchInitiated CoverageNeutralN/A
(Data available from 6/24/2016 forward)
PerkinElmer logo
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $154.65
Low: $153.16
High: $155.67

50 Day Range

MA: $140.80
Low: $127.81
High: $154.65

52 Week Range

Now: $154.65
Low: $93.23
High: $162.70


860,359 shs

Average Volume

941,161 shs

Market Capitalization

$17.33 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of PerkinElmer?

The following Wall Street analysts have issued stock ratings on PerkinElmer in the last twelve months: BMO Capital Markets, Cfra, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, JPMorgan Chase & Co., KeyCorp, Needham & Company LLC, Robert W. Baird, Smith Barney Citigroup, Stifel Nicolaus, The Goldman Sachs Group, Inc., Wells Fargo & Company, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for PKI.

What is the current price target for PerkinElmer?

11 Wall Street analysts have set twelve-month price targets for PerkinElmer in the last year. Their average twelve-month price target is $141.73, suggesting a possible downside of 7.5%. Needham & Company LLC has the highest price target set, predicting PKI will reach $193.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $45.00 for PerkinElmer in the next year.
View the latest price targets for PKI.

What is the current consensus analyst rating for PerkinElmer?

PerkinElmer currently has 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PKI will outperform the market and that investors should add to their positions of PerkinElmer.
View the latest ratings for PKI.

What other companies compete with PerkinElmer?

How do I contact PerkinElmer's investor relations team?

PerkinElmer's physical mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company's listed phone number is 781-663-6900 and its investor relations email address is [email protected] The official website for PerkinElmer is www.perkinelmer.com.